Testing Counseling and Mobile Health Interventions to Improve Physical Activity and Diet Quality in Survivors of Childhood Cancer
Launched by FRED HUTCHINSON CANCER CENTER · Sep 29, 2021
Trial Information
Current as of July 23, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
OUTLINE: Patients are randomized to Arms 1, 2, or 3.
ARM 1: Patients receive a personalized clinician-led self-management telehealth session at baseline and 2 months. Patients with poor response at 3 months are randomized to Arm 2 or 4, otherwise patients receive the same telehealth session at months 4 and 6. Patients may receive 2 additional telehealth sessions after 6 months.
ARM 2: Patients receive personalized goal setting for daily steps and activity (updated weekly) and 3 dietary goals (updated monthly) with social media peer support for 6 months. Patients with poor response at 3 mo...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Childhood Cancer Survivor Study (CCSS) participant who is between age 18 to \< 55 years at time of initial approach
- • Moderate to high CV risk status based on CCSS risk prediction models for cardiomyopathy and ischemic heart disease
- • Able to read, write, and speak English
- • Ability to understand and the willingness to provide informed consent
- * At least one of the following:
- • Less than 30 minutes/day of moderate to vigorous physical activity (MVPA) based on validated self-report instrument (Godin)
- • Healthy Eating Index (HEI)-2015 score \< 60 per study food frequency questionnaire (FFQ)
- • Body mass index (BMI) \>= 25 kg/m\^2 per self-reported height and weight
- • Be free of any known (self-reported) ischemic heart disease or cardiomyopathy
- • Have internet access (can be via smartphone or computer; if neither device is available, the study can loan participants a Wi-Fi enabled device, but participant will need to have access to the internet)
- Exclusion Criteria:
- • Individuals with known cardiomyopathy or ischemic heart disease based on prior CCSS surveys are excluded. While not likely to be common, participants who newly report in our study's screening questionnaire that they have newly diagnosed cardiomyopathy or ischemic heart disease will also be excluded
- • Having any self-reported contraindication to walking or being physically active
- • Not currently known to be pregnant; individuals known to be pregnant and otherwise eligible for the study can be enrolled once no longer known to be pregnant. Participants who report being pregnant after randomization can remain in the study
- • Individuals receiving active cancer treatment. Participants who report starting active cancer treatment after randomization can remain in the study
About Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center is a leading nonprofit research institution dedicated to the pursuit of innovative cancer treatments and prevention strategies. Established in Seattle, Washington, the center is renowned for its pioneering work in hematopoietic cell transplantation and its commitment to advancing cancer research through collaborative clinical trials. By integrating cutting-edge science with compassionate patient care, Fred Hutchinson Cancer Center aims to improve outcomes for patients while fostering a multidisciplinary approach to tackling complex cancer challenges. With a strong emphasis on translating research findings into clinical applications, the center is at the forefront of developing novel therapies that offer hope to patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Memphis, Tennessee, United States
Seattle, Washington, United States
Patients applied
Trial Officials
Eric J. Chow
Principal Investigator
Fred Hutch/University of Washington Cancer Consortium
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials